ARCHIVES

FDA Committee Oks AMSA for Group C List, Tables THC Request, Deadlocks On Estramustine NDA

This article is from The Cancer Letter archive.

Vol. 07 No. 27 | July 3, 1981

Download PDF Visit The Full Archive

Related Articles

Cancer Program Critics Called “Irresponsible,” Demagogues”

March 21, 1975

NCI Finds Physician Recommendation Drives Patient Demand For ABMT

July 19, 1996

High-Dose Chemo, Stem Cell Transplant No Benefit For Node+ Breast Cancer

January 25, 2008

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

November 7, 1980

ASCO, FDA Website To Help Demystify Expanded Access

June 25, 2010

FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies.

December 7, 2007